Patients with mantle cell lymphoma (MCL), particularly those with p53
mutations and those who have a poor prognosis, should be treated with targeted therapy upfront, said Ezzat Elhassadi, MD.
In a study presented at the 2019 European Hematology Association Congress, 29 patients with MCL were observed over a 10-year period. Researchers found that patients harboring p53
mutations correlated directly with overall survival (OS). Median OS in the 20% of patients with p53
-mutated disease was approximately 4 years; OS had not been reached in the wild-type subset (P
“From these data, we are advocating about using targeted therapy upfront in MCL—especially in patients who are not fit for the standard of care, including autologous stem cell transplant (ASCT),” explained Elhassadi, a consultant hematologist at University Hospital Waterford. “Potentially, if we use our targeted therapy early in the disease course upfront, there are data supporting that the response rates will be better.”